Nirmish Singla1, Ryan C Hutchinson2, Rashed A Ghandour2, Yuval Freifeld2, Dong Fang3, Arthur I Sagalowsky2, Yair Lotan2, Aditya Bagrodia2, Vitaly Margulis4, Hans J Hammers5, Solomon L Woldu6. 1. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. 3. Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. 4. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, I.M. Sechenov First Moscow State University, Moscow, Russia. 5. Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. 6. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: solomon.woldu@utsouthwestern.edu.
Abstract
OBJECTIVES: Despite immune checkpoint inhibitor (ICI) approval for metastatic renal cell carcinoma (mRCC) in 2015, cytoreductive nephrectomy (CN) is guided by extrapolation from earlier classes of therapy. We evaluated survival outcomes, timing, and safety of combining CN with modern immunotherapy (IO) for mRCC. METHODS: From 96,329 renal cancer cases reported to the NCDB between 2015 and 2016, we analyzed 391 surgical candidates diagnosed with clear cell mRCC treated with IO ± CN and no other systemic therapies. Primary outcome was overall survival (OS) stratified by the performance of CN (CN + IO vs. IO alone). Secondary outcomes included OS stratified by the timing of CN, pathologic findings, and perioperative outcomes. RESULTS: Of 391 patients, 221 (56.5%) received CN + IO and 170 (43.5%) received IO only. Across a median follow-up of 14.7 months, patients who underwent CN + IO had superior OS (median NR vs. 11.6 months; hazard ratio 0.23, P < 0.001), which was upheld on multivariable analyses. IO before CN resulted in lower pT stage, grade, tumor size, and lymphovascular invasion rates compared to upfront CN. Two of 20 patients (10%) undergoing CN post-IO achieved complete pathologic response in the primary tumor (pT0). There were no positive surgical margins, 30-day readmissions, or prolonged length of stay in patients undergoing delayed CN. CONCLUSION: Using a large, national, registry-based cohort, we provide the first report of survival outcomes in mRCC patients treated with CN combined with modern IO. Our findings support an oncologic role for CN in the ICI era and provide preliminary evidence regarding the timing and safety of CN relative to IO administration.
OBJECTIVES: Despite immune checkpoint inhibitor (ICI) approval for metastatic renal cell carcinoma (mRCC) in 2015, cytoreductive nephrectomy (CN) is guided by extrapolation from earlier classes of therapy. We evaluated survival outcomes, timing, and safety of combining CN with modern immunotherapy (IO) for mRCC. METHODS: From 96,329 renal cancer cases reported to the NCDB between 2015 and 2016, we analyzed 391 surgical candidates diagnosed with clear cell mRCC treated with IO ± CN and no other systemic therapies. Primary outcome was overall survival (OS) stratified by the performance of CN (CN + IO vs. IO alone). Secondary outcomes included OS stratified by the timing of CN, pathologic findings, and perioperative outcomes. RESULTS: Of 391 patients, 221 (56.5%) received CN + IO and 170 (43.5%) received IO only. Across a median follow-up of 14.7 months, patients who underwent CN + IO had superior OS (median NR vs. 11.6 months; hazard ratio 0.23, P < 0.001), which was upheld on multivariable analyses. IO before CN resulted in lower pT stage, grade, tumor size, and lymphovascular invasion rates compared to upfront CN. Two of 20 patients (10%) undergoing CN post-IO achieved complete pathologic response in the primary tumor (pT0). There were no positive surgical margins, 30-day readmissions, or prolonged length of stay in patients undergoing delayed CN. CONCLUSION: Using a large, national, registry-based cohort, we provide the first report of survival outcomes in mRCC patients treated with CN combined with modern IO. Our findings support an oncologic role for CN in the ICI era and provide preliminary evidence regarding the timing and safety of CN relative to IO administration.
Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245
Authors: Hyung L Kim; Eddie Mayerson; Primo N Lara; Edward Messing; Cathy Tangen; Brian M Shuch; Ulka Vaishampayan Journal: Eur Urol Focus Date: 2019-05-16
Authors: Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles Journal: N Engl J Med Date: 2019-02-16 Impact factor: 91.245
Authors: Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier Journal: N Engl J Med Date: 2018-03-21 Impact factor: 91.245
Authors: M E Gore; C Szczylik; C Porta; S Bracarda; G A Bjarnason; S Oudard; S-H Lee; J Haanen; D Castellano; E Vrdoljak; P Schöffski; P Mainwaring; R E Hawkins; L Crinò; T M Kim; G Carteni; W E E Eberhardt; K Zhang; K Fly; E Matczak; M J Lechuga; S Hariharan; R Bukowski Journal: Br J Cancer Date: 2015-06-18 Impact factor: 7.640
Authors: Craig Labbate; Ken Hatogai; Ryan Werntz; Walter M Stadler; Gary D Steinberg; Scott Eggener; Randy F Sweis Journal: J Immunother Cancer Date: 2019-03-11 Impact factor: 13.751
Authors: Pooja Ghatalia; Elizabeth A Handorf; Daniel M Geynisman; Mengying Deng; Matthew R Zibelman; Philip Abbosh; Fern Anari; Richard E Greenberg; Rosalia Viterbo; David Chen; Marc C Smaldone; Alexander Kutikov; Robert G Uzzo Journal: J Urol Date: 2022-02-25 Impact factor: 7.600
Authors: Benjamin J Lichtbroun; Arnav Srivastava; Sai Krishnaraya Doppalapudi; Kevin Chua; Eric A Singer Journal: Cancers (Basel) Date: 2022-05-27 Impact factor: 6.575
Authors: Alexandra L Tabakin; Mark N Stein; Christopher B Anderson; Charles G Drake; Eric A Singer Journal: Transl Cancer Res Date: 2020-11 Impact factor: 1.241
Authors: Aafke Meerveld-Eggink; Niels Graafland; Sofie Wilgenhof; Johannes V Van Thienen; Ferry Lalezari; Michael Grant; Bernadett Szabados; Yasmin Abu-Ghanem; Teele Kuusk; Ekaterini Boleti; Christian U Blank; John B A G Haanen; Thomas Powles; Axel Bex Journal: Eur Urol Open Sci Date: 2022-01-03